dinutuximab + aldesleukin + sargramostim + isotretinoin

This combination immunotherapy regimen is a multi-agent protocol developed and studied by the University of Cologne for the treatment of high-risk neuroblastoma. The regimen consists of the anti-GD2 monoclonal antibody **dinutuximab** (or dinutuximab beta), the cytokines **aldesleukin** (interleukin-2) and **sargramostim** (GM-CSF), and the differentiating agent **isotretinoin** (13-cis-retinoic acid). The mechanism of action involves dinutuximab targeting the ganglioside GD2 expressed on neuroblastoma cells, which facilitates antibody-dependent cellular cytotoxicity (ADCC). The cytokines aldesleukin and sargramostim are included to stimulate and expand effector cell populations, such as natural killer (NK) cells and granulocytes, thereby enhancing the immune-mediated destruction of tumor cells. Isotretinoin is used to induce differentiation and inhibit the proliferation of residual neuroblastoma cells. A key focus of the University of Cologne's research (e.g., NCT01592045) has been the optimization of aldesleukin administration, specifically comparing subcutaneous versus intravenous delivery to reduce systemic toxicities like capillary leak syndrome and pain while maintaining therapeutic efficacy.

Brand names

Qarziba

Other names

anti-GD2 + IL-2 + GM-CSF + isotretinoinCologne Regimendinutuximab beta + aldesleukin + sargramostim + isotretinoin